Regeneron Pharmaceuticals (NASDAQ: REGN) reported fourth-quarter results that beat expectations, and investors -- who have been snapping up the stock this week based on news that it's working on a treatment for the 2019n-CoV coronavirus -- bid up the shares another 5%. Revenue rose 13% in the quarter to $2.17 billion, topping analysts' consensus estimate of $2.11 billion. Non-GAAP earnings per share rose 10% to $7.50, beating expectations of $6.92.
Regeneron's growth was driven by its eye drug Eylea, sales of which were up 11% in the quarter, and inflammation-reducer Dupixent, which had global sales growth of 136%. The company partners with Bayer for Eylea sales outside the U.S., and with Sanofi for worldwide sales of Dupixent.
Image source: Getty Images.